Eli Lilly also announced a $6 billion biotech facility in Alabama that will manufacture peptide-based drugs, including future GLP-1 and related therapies. This project marks one of the largest investments in peptide API production globally, reflecting the belief that peptides are a critical long-term segment of the pharmaceutical supply chain. Reuters➡️ Beyond headline drug results, this signals industrial commitment to peptides as sustainable, scalable therapeutic platforms.

---